During the last three months, 4 analysts shared their evaluations of bluebird bio (NASDAQ:BLUE), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 0 | 3 | 1 | 0 |
Last 30D | 0 | 0 | 2 | 0 | 0 |
1M Ago | 0 | 0 | 1 | 1 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for bluebird bio, presenting an average target of $2.92, a high estimate of $6.00, and a low estimate of $1.02. Highlighting a 5.81% decrease, the current average has fallen from the previous average price target of $3.10.
Decoding Analyst Ratings: A Detailed Look
In examining recent analyst actions, we...
Login or create a forever free account to read this news
Sign up/Log in